Polymerase Chain Reaction Market Size, Share, Industry, Forecast and outlook (2024-2031)

Polymerase Chain Reaction Market is Segmented By Type (Standard PCR Systems, Digital PCR Systems, Real-time PCR Systems), By Product (Instruments, Reagents and Consumables, Software), By Indication (Infectious Diseases, Oncology, Genetic Disorders, Others), By End-User (Hospitals & Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Industries, Academic and Research Organizations, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Polymerase Chain Reaction Market Overview

The Polymerase Chain Reaction Market size was valued at a CAGR of 2.39 % during the forecast period (2023-2030). Polymerase chain reaction (PCR) is a molecular diagnostic procedure that creates numerous copies of a DNA segment. To generate millions of copies of DNA sequencing precisely, a PCR machine is used to regulate the temperature of the material in an autonomous and pre-programmed operation. This technology detects tuberculosis, AIDS, infections, and Lyme disease by identifying and cultivating disease-causing bacteria. As a result, it has a wide range of applications in life science domains like genetics, biotechnology, molecular biology, drug development, and clinical diagnostics.

Polymerase Chain Reaction Market Summary

To Know More: Download Sample

Polymerase Chain Reaction Market Dynamics 

Advancement in Polymerase Chain Reaction for detecting SARS-CoV-2 is expected to drive market growth.

The novel human coronavirus SARS-CoV-2 (also known as 2019-nCoV) continues to spread worldwide. The most common method for detecting viruses is the real-time reverse transcription-polymerase chain reaction (rRT-PCR). However, possible false-negative and false-positive results can lead to inaccurate conclusions, necessitating improving current procedures. A multiplex rRT-PCR diagnostic technique concurrently targets two viral genes (RdRP and E) and one human gene (RP). The process was investigated using a template of pseudo viral RNA and human target mRNA sequences. In addition, 14 clinical SARS-CoV-2 positive samples are used to confirm the methodology. The findings match those of the CDC-approved Cepheid's Xpert Xpress SARS-CoV-2 diagnostic system (100 percent ). Unlike single gene targeting methodologies, the current approach amplifies two viral areas in the same PCR experiment. As a result, an accurate SARS-CoV-2 diagnostic test was developed, with each run allowing for 91 samples in 96-well plates. SARS-CoV-2 can now be diagnosed using a fast, reliable, and simple rRT-PCR approach, thanks to this strategy. Thus, from the above statements, the market is expected to drive in the forecast period.

Polymerase Chain Reaction Market Segmentation Analysis

Real-time PCR Systems segment is expected to hold the largest market share in polymerase chain reaction market

The real-time PCR systems segment is expected to dominate in 2020. The segment benefits because the primary advantage of real-time PCR is identifying amplified fragments during the PCR process. Real-time PCR measures the amount of the product during the exponential phase, whereas standard PCR measures the product during the plateau phase. It is more effective to measure during the exponential phase because measurements taken during the plateau phase do not always clearly indicate the quantity of starting material. Moreover, the advantage of real-time PCR over standard PCR is that the entire process from amplification to analysis is performed in the same tube. This differs from standard PCR, where the PCR product is moved and manipulated into other formats. As a result, there is a decreased possibility of contaminating the product with real-time PCR methods. Thus, from the above statements, it has increased the demand, due to which the market segment is expected to hold the largest market share in the forecast period.

Polymerase Chain Reaction Market Geographical Share

North America region holds the largest market share in the global polymerase chain reaction market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of infectious disease, favorable government initiatives, flexible regulatory guidelines, an increase in the number of diagnostics product launches, and the use of diagnostics to identify COVID-19 in an emergency in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, COVID-19 cases are increasing rapidly, and the spread of the virus is very rapid, speeding up the transmission. The US remains severely affected by the coronavirus disease 2019 (COVID-19) pandemic, with more than 9 million cases and 230 000 deaths reported in 2020. The increasing count of suspects increases the number of diagnostic tests, boosting the market growth in the country. Moreover, The Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results in genetic analysis and research within 90 minutes, was introduced in October 2021 by Thermo Fisher Scientific, a provider of scientific instrumentation, reagents, and consumables based in the United States.

Additionally, In the United States, there is also a growing trend of genetic engineering and genomic research in academia and the biotechnology industry. The rising demand for targeted and precision medicine for the management of chronic illnesses and the need to understand the genetic and molecular basis of disease are driving the growth of genomic research. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Polymerase Chain Reaction Companies and Competitive Landscape

Major key players in the polymerase chain reaction market are Abbott Laboratories, Agilent Technologies Inc., Thermo Fisher Scientific Inc., BioMerieux SA, Siemens Healthineers, Qiagen, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation  and Cytiva.

Abbott Laboratories:

Overview:

Abbott Laboratories (Abbott) develops, manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.

ABBOTT REALTIME CMV: The Abbott RealTime CMV assay is an in vitro polymerase chain reaction (PCR) assay for the quantitation of cytomegalovirus (CMV) DNA in human plasma or whole blood.